Head and Neck Squamous Cell Carcinoma - Pipeline Insights, 2016; New Report Launched
Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all 99 pipeline drugs that fall under the category of Head and Neck Squamous Cell Carcinoma. Eli Lilly's Exbitux (Cetuximab) is the first monoclonal antibody for head and neck cancer.
View full press release